-
Canopy Growth Sues GW Pharma, Alleges Unauthorized Use Of Intellectual Property
Monday, December 28, 2020 - 12:50pm | 357Read More...Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) filed an federal lawsuit last week against Britain’s GW Pharma (NASDAQ: GWPH). In the lawsuit filed in the U.S. District Court for the Western District of Texas, Canopy accuses GW Pharma of unauthorized usage of Canopy’s...
-
GW Pharma Details Positive Results Of Epidiolex Study In Patients With TSC-Related Seizures
Tuesday, December 22, 2020 - 11:52am | 406Read More...GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology. Epidiolex is the first FDA-authorized CBD medicine for...
-
PreMarket Prep Stock Of The Day: GW Pharmaceuticals
Thursday, December 3, 2020 - 1:39pm | 702Read More...Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given...
-
GW Pharmaceuticals Revenue Hits $137M, Tests Another Cannabis Plant-Based Drug
Tuesday, November 3, 2020 - 12:00pm | 402Read More...Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year. For the first nine months of this fiscal year, total revenue amounted to $378.6 million versus $202.3 million for the...
-
DEA Deschedules Expidiolex; GW Pharma's CBD Epilepsy Treatment No Longer A Controlled Substance
Tuesday, April 7, 2020 - 10:11am | 379Read More...GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance. “This notification from DEA fully establishes that EPIDIOLEX...
-
FDA Grants GW Pharmaceuticals Priority Review For Cannabidiol Drug In Seizure Condition
Wednesday, April 1, 2020 - 11:20am | 472Read More...A drug from GW Pharmaceuticals plc (NASDAQ: GWPH) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food and Drug Administration. The Cambridge, U.K.-based company and its subsidiary Greenwich Biosciences Inc. confirmed Tuesday...
-
GW Pharma Submits CBD Seizure Treatment To European Medicines Agency For Approval
Friday, March 13, 2020 - 9:23am | 350Read More...GW Pharmaceuticals plc (NASDAQ: GWPH) said Friday it has submitted a Type II Variation Application to the European Medicines Agency, applying for authorization of its Epidyolex — Epidiolex in the U.S. — cannabidiol oral solution for the management of seizures related to tuberous...
-
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
Wednesday, February 26, 2020 - 1:55pm | 485Read More...GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus estimate by 68 cents . This is a 65% increase over losses of 20 cents per share from the same...
-
Can CBD Help With Opioid Withdrawal? Johns Hopkins Researchers Aim To Find Out By Testing Epidiolex in This Context
Tuesday, February 18, 2020 - 12:55pm | 269Read More...More than 130 people a day lose their lives from opioid-connected drug overdose, according to the Health Resources and Services Administration. Because of these and similar devastating statistics that clearly depict the real status of the opioid epidemic in the country, more and more researchers...
-
BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex
Tuesday, February 4, 2020 - 12:02pm | 446Read More...GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), which derives a lion's share of its revenues from its cannabinoid seizure drug Epidiolex, provides value for investors due to the potential for the drug to have wide utility over both orphan and non-orphan indications, according to BofA Securities....
-
GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year
Thursday, January 16, 2020 - 12:16pm | 479Read More...GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) exceeded fourth-quarter estimates for Epidiolex sales, notching $108 million in revenue for the CBD drug, according to the company's preliminary figures. The earnings preview triggered a brief run in the stock this week — one bulls...
-
GW Pharma Reports Preliminary Q4 Revenue Of $108M, 'Exceptional' Launch Year For Epidiolex
Monday, January 13, 2020 - 11:54am | 339Read More...GW Pharmaceuticals plc (NASDAQ: GWPH) issued preliminary unaudited fourth-quarter financial results Sunday that show total net product sales of around $108 million. The company posted preliminary net sales of $309 million for the full year ended Dec. 3. Net Epidiolex sales were projected...
-
'Exceeded Our Expectations': First Latin American Study On CBD, Epilepsy Completed
Saturday, December 7, 2019 - 8:50am | 539Read More...A research team at Garrahan Children’s Hospital, a public pediatric research hospital in Buenos Aires, Argentina, completed the continent’s first clinical trials on CBD. The study adds overwhelming evidence of the compound’s efficacy in treating refractory epilepsy in children....
-
Brace For Stricter FDA Regulation Of CBD Consumer Products, Analysts Say
Tuesday, November 26, 2019 - 4:45pm | 490Read More...Cannabis stocks headed lower Tuesday after a Monday communication from the FDA, which sent warning letters to 13 companies for illegally selling products containing containing cannabidiol (CBD), violating the Federal Food, Drug, and Cosmetic Act. The 15 companies were warned for...
-
Analyst: New UK Cannabis Regulations Limit Usage, Call For Additional Research
Thursday, November 14, 2019 - 3:49pm | 390Read More...New guidelines issued in the United Kingdom for the consumption and prescription of cannabis issued by the National Institute for Health Care and Excellence fell short of expectations, according to Cantor Fitzgerald. What Happened The guidelines are an example of the challenges that Canadian...
